Osteosarcoma: Oncologic and functional results. A single institutional report covering 22 years, Journal of Surgical Oncology, vol.80, issue.3, pp.124-129, 1999. ,
DOI : 10.1002/(SICI)1096-9098(199911)72:3<124::AID-JSO3>3.0.CO;2-G
Neoadjuvant chemotherapy for osteosarcoma of the extremity, European Journal of Cancer, vol.37, issue.16, pp.2030-2039, 2001. ,
DOI : 10.1016/S0959-8049(01)00229-5
Progress in human tumour immunology and immunotherapy, Nature, vol.411, issue.6835, pp.380-384, 2001. ,
DOI : 10.1038/35077246
Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression, International Journal of Cancer, vol.73, issue.6, pp.986-991, 2000. ,
DOI : 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B
Interleukin-12 Enhances the Sensitivity of Human Osteosarcoma Cells to 4-Hydroperoxycyclophosphamide by a Mechanism Involving the Fas/Fas-Ligand Pathway, Clinical Cancer Research, vol.10, issue.2, pp.777-783, 2004. ,
DOI : 10.1158/1078-0432.CCR-1245-02
Interferon-? sensitizes osteosarcoma cells to fas-induced apoptosis by up-regulating fas receptors and caspase-8, Pediatric Blood & Cancer, vol.5, issue.7, pp.729-736, 2004. ,
DOI : 10.1002/pbc.20151
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.532-538, 2002. ,
DOI : 10.1007/s00262-002-0313-3
Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.539-546, 2002. ,
DOI : 10.1007/s00262-002-0315-1
Fas expression inversely correlates with metastatic potential in osteosarcoma cells, Oncology Reports, vol.9, pp.823-827, 2002. ,
DOI : 10.3892/or.9.4.823
Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells, Clinical Cancer Research, vol.10, issue.23, pp.8114-8119, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0353
FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells, Oncogene, vol.22, issue.58, pp.9231-9242, 2003. ,
DOI : 10.1038/sj.onc.1207184
Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP, Cell Death and Differentiation, vol.12, issue.1, pp.10-18, 2005. ,
DOI : 10.1038/sj.cdd.4401507
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells, Proceedings of the National Academy of Sciences, vol.99, issue.25, pp.16168-16173, 2002. ,
DOI : 10.1073/pnas.242600099
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients, J Immunol, vol.161, pp.6970-6976, 1998. ,
Vaccination with Mage-3a1 Peptide???Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma, The Journal of Experimental Medicine, vol.18, issue.11, pp.1669-1678, 1999. ,
DOI : 10.1073/pnas.96.5.2268
The biology of natural killer cells: Insights into molecular basis of function In: The Natural Killer Cell, pp.2-40, 1992. ,
Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanisms, In Vitro Cellular & Developmental Biology - Animal, vol.170, issue.9-10, pp.657-662, 1992. ,
DOI : 10.1007/BF02631041
Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104, Clin Cancer Res, vol.5, pp.1868-1875, 1999. ,
Hyperthermia increases the susceptibility of chondro-and osteosarcoma cells to natural killer cell-mediated lysis, Anticancer Res, vol.22, pp.789-792, 2002. ,
Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer, Cancer Immunology, Immunotherapy, vol.53, issue.3, pp.227-233, 2004. ,
DOI : 10.1007/s00262-003-0481-9
HEAT-SHOCK PROTEIN 72 IN HUMAN OSTEOSARCOMA: T-Lymphocyte Reactivity and Cytotoxicity, Pediatric Hematology and Oncology, vol.87, issue.5, pp.355-364, 2000. ,
DOI : 10.1080/08880010050034283
Dendritic cells as therapeutic vaccines against cancer, Nature Reviews Immunology, vol.10, issue.4, pp.296-306, 2005. ,
DOI : 10.1007/s00262-003-0429-0
Active immunization against cancer with dendritic cells: The near future, International Journal of Cancer, vol.94, issue.4, pp.459-473, 2001. ,
DOI : 10.1002/ijc.1503
Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells, The Lancet, vol.356, issue.9236, pp.1163-1165, 2000. ,
DOI : 10.1016/S0140-6736(00)02762-8
Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin, Clin Cancer Res, vol.1, pp.1595-1601, 1995. ,
Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl Tripeptide, JNCI Journal of the National Cancer Institute, vol.81, issue.12, pp.935-938, 1989. ,
DOI : 10.1093/jnci/81.12.935
Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells, Cancer Biotherapy & Radiopharmaceuticals, vol.14, issue.2, pp.121-128, 1999. ,
DOI : 10.1089/cbr.1999.14.121
Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma, American Journal of Clinical Oncology, vol.18, issue.2, pp.93-99, 1995. ,
DOI : 10.1097/00000421-199504000-00001
Unique histological changes in lung metastasis of osteosarcoma patients following therapy with liposomal muramyl tripeptide ,
Adhesion molecules and tumor metastasis, Human Pathology, vol.29, issue.9, pp.889-892, 1998. ,
DOI : 10.1016/S0046-8177(98)90191-5
A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo, Clin Cancer Res, vol.9, pp.6560-6566, 2003. ,
A review of recent findings involving interleukin-2-based cancer therapy, Current Opinion in Oncology, vol.16, issue.6, pp.542-546, 2004. ,
DOI : 10.1097/01.cco.0000142070.45097.68
Immunomodulation in a treatment program including pre-and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma, Tumori, vol.3, pp.263-268, 2003. ,
A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A pediatric oncology group study, Cancer, vol.23, issue.4, pp.783-788, 1989. ,
DOI : 10.1002/1097-0142(19890815)64:4<783::AID-CNCR2820640402>3.0.CO;2-F
Interleukin-12 Induces Efficient Lysis of Natural Killer-Sensitive and Natural Killer-Resistant Human Osteosarcoma Cells: the Synergistic Effect of Interleukin-2, Scandinavian Journal of Immunology, vol.4, issue.1, pp.618-625, 2000. ,
DOI : 10.1038/sj.gt.3300779
Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells, Cytokines, Cellular & Molecular Therapy, vol.7, issue.4, pp.135-142, 2002. ,
DOI : 10.1080/13684730310001977
Inhibition by Interleukin-18 of the Growth of Dunn Osteosarcoma Cells, Journal of Interferon & Cytokine Research, vol.24, issue.3, pp.161-167, 2004. ,
DOI : 10.1089/107999004322917007
IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis, Clinical and Experimental Immunology, vol.130, issue.3, pp.344-349, 2003. ,
DOI : 10.1016/8756-3282(94)90305-0
Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models, Cancer Res, vol.56, pp.4614-4619, 1996. ,
Concurrent induction of T-cell activation and apoptosis of osteosarcoma cells by adenovirus-mediated B7-1/Fas chimeric gene transfer, Cancer Gene Therapy, vol.10, issue.9, pp.717-725, 2003. ,
DOI : 10.1038/sj.cgt.7700624
Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein, Cancer Res, vol.56, pp.2245-2249, 1996. ,
DOI : 10.1073/pnas.91.21.9837
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC44912
Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression, Biochemical and Biophysical Research Communications, vol.320, issue.1, pp.138-144, 2004. ,
DOI : 10.1016/j.bbrc.2004.05.135
p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome, Molecular Cancer Therapeutics, vol.4, issue.4, pp.53-625, 2005. ,
DOI : 10.1158/1535-7163.MCT-04-0196
Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes, The Journal of Gene Medicine, vol.73, issue.Pt 3, pp.407-419, 2005. ,
DOI : 10.1002/jgm.684
Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases, Clin Cancer Res, vol.6, pp.3713-3718, 2000. ,
Interleukin (IL)-12 and IL-12 gene transfer upregulate Fas expression in human osteosarcoma and breast cancer cells, Cancer Res, vol.61, pp.4066-4071, 2001. ,
Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth, Anticancer Res, vol.23, pp.1173-1179, 2003. ,
Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL- 23/IL-18 gene transfer in a rat osteosarcoma model, Anticancer Res, vol.24, pp.2861-2867, 2004. ,
Gene therapy clinical trials worldwide 1989???2004???an overview, The Journal of Gene Medicine, vol.6, issue.6, pp.597-602, 2004. ,
DOI : 10.1002/jgm.619
Gene therapy eradicating distant disseminated micro-metastases by optimal cytokine expression in the primary lesion only: Novel concepts for successful cytokine gene therapy, International Journal of Oncology, vol.24, pp.549-558, 2004. ,
DOI : 10.3892/ijo.24.3.549
High-Level Expression of the Coxsackievirus and Adenovirus Receptor Messenger RNA in Osteosarcoma, Ewing's Sarcoma, and Benign Neurogenic Tumors among Musculoskeletal Tumors, Clinical Cancer Research, vol.10, issue.11, pp.3831-3838, 2004. ,
DOI : 10.1158/1078-0432.CCR-03-0345
Coxsackievirus and Adenovirus Receptor Expression on Primary Osteosarcoma Specimens and Implications for Gene Therapy with Recombinant Adenoviruses, Clinical Cancer Research, vol.11, issue.6, pp.2445-2447, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-2375
Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma., Journal of Clinical Oncology, vol.14, issue.2, pp.467-472, 1996. ,
DOI : 10.1200/JCO.1996.14.2.467
Conditionally Replicative Adenovirus with Tropism Expanded towards Integrins Inhibits Osteosarcoma Tumor Growth in Vitro and in Vivo, Clinical Cancer Research, vol.10, issue.1, pp.61-67, 2004. ,
DOI : 10.1158/1078-0432.CCR-0609-03
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Molecular Genetics and Metabolism, vol.80, issue.1-2, pp.148-158, 2003. ,
DOI : 10.1016/j.ymgme.2003.08.016
Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy, International Journal of Oncology, vol.25, pp.1753-1762, 2004. ,
DOI : 10.3892/ijo.25.6.1753
Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy, International Journal of Molecular Medicine, vol.13, pp.705-710, 2004. ,
DOI : 10.3892/ijmm.13.5.705
On the road to a tumor cell vaccine: 20 years of cellular immunotherapy, Vaccine, vol.23, issue.1, pp.97-113, 2004. ,
DOI : 10.1016/j.vaccine.2003.12.036
Cancer immunotherapy: hopes and pitfalls: a review, Anticancer Res, vol.16, pp.3235-3240, 1996. ,
Spontaneous regression of lung metastases from osteosarcoma, Cancer, vol.3, issue.10, pp.2798-2803, 1994. ,
DOI : 10.1002/1097-0142(19941115)74:10<2798::AID-CNCR2820741009>3.0.CO;2-2
Osteosarcoma of the abdominal wall with spontaneous regression of lung metastases., American Journal of Roentgenology, vol.171, issue.3, pp.691-692, 1998. ,
DOI : 10.2214/ajr.171.3.9725297
Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line, Journal of Orthopaedic Science, vol.8, issue.4, pp.554-559, 2003. ,
DOI : 10.1007/s00776-003-0663-5
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity, J Immunol, vol.137, pp.3042-3048, 1986. ,
Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma, The Journal of Immunology, vol.169, issue.3, pp.1611-1618, 2002. ,
DOI : 10.4049/jimmunol.169.3.1611
Antigenicity of fusion proteins from sarcomaassociated chromosomal translocations, Cancer Res, vol.61, pp.6868-6875, 2001. ,
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proceedings of the National Academy of Sciences, vol.96, issue.7, pp.3540-3545, 1999. ,
DOI : 10.1073/pnas.96.7.3540
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation, Cell, vol.93, issue.2, pp.165-176, 1998. ,
DOI : 10.1016/S0092-8674(00)81569-X
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-319, 1997. ,
DOI : 10.1016/S0092-8674(00)80209-3
Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis, Biochemical and Biophysical Research Communications, vol.234, issue.1, pp.137-142, 1997. ,
DOI : 10.1006/bbrc.1997.6603
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proceedings of the National Academy of Sciences, vol.95, issue.7, pp.3597-3602, 1998. ,
DOI : 10.1073/pnas.95.7.3597
Receptor Activator of Nuclear Factor ??B Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis, The American Journal of Pathology, vol.163, issue.5, pp.2021-2031, 2003. ,
DOI : 10.1016/S0002-9440(10)63560-2
Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and Cytokines, Biochemical and Biophysical Research Communications, vol.250, issue.3, pp.776-781, 1998. ,
DOI : 10.1006/bbrc.1998.9394
Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis, Endocrinology, vol.140, issue.10, pp.4382-4389, 1999. ,
DOI : 10.1210/en.140.10.4382
Loss of RANKL, a TNF-alpha ligand family member, in sporadic osteosarcoma, J Bone Miner Res, vol.14, issue.1, p.37, 1999. ,
OPG: new therapeutic targets in bone tumours and associated osteolysis, Biochim Biophys Acta, vol.1704, pp.49-57, 2004. ,
URL : https://hal.archives-ouvertes.fr/inserm-00669006
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord, Nat Med, vol.6, pp.521-528, 2000. ,
TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell???specific Survival Factor, The Journal of Experimental Medicine, vol.372, issue.12, pp.2075-2080, 1997. ,
DOI : 10.1084/jem.183.1.7
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, vol.390, issue.6656, pp.175-179, 1997. ,
DOI : 10.1038/36593
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL, Journal of Biological Chemistry, vol.273, issue.23, pp.14363-14367, 1998. ,
DOI : 10.1074/jbc.273.23.14363
Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL-Induced Apoptosis, Journal of Bone and Mineral Research, vol.107, issue.Suppl, pp.1712-1721, 2004. ,
DOI : 10.1359/JBMR.040703
Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-343, 2004. ,
DOI : 10.1016/j.molmed.2004.05.007
Quantitative Structure???Activity Relationships for ???? T Cell Activation by Bisphosphonates, Journal of Medicinal Chemistry, vol.47, issue.2, pp.375-384, 2004. ,
DOI : 10.1021/jm0303709